ClinicalTrials.Veeva

Menu

Vagus Nerve Stimulation for Autonomic Modulation After Coronary Artery Bypass Graft Surgery (ENV)

H

Hospital de Clinicas de Porto Alegre

Status

Completed

Conditions

Vagus Nerve Stimulations
Coronary Artery Bypass Grafting (CABG) Surgery

Treatments

Device: Transcutaneous auricular vagus nerve stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT07853222
90487825.4.1001.5327 (Registry Identifier)
7.780.341 (Registry Identifier)
2025-0338

Details and patient eligibility

About

The objective of this randomized clinical trial is to investigate whether transcutaneous auricular vagus nerve stimulation (taVNS) can improve the recovery of patients undergoing coronary artery bypass grafting (CABG) through autonomic modulation, while also evaluating the safety of the intervention.

The main questions this study aims to answer are:

  • Does taVNS improve autonomic modulation, as assessed by heart rate variability, in patients undergoing CABG?
  • Does taVNS reduce the inflammatory response and pain intensity while improving quality of life and functional capacity during the postoperative period?
  • Is taVNS a safe and well-tolerated intervention during recovery after CABG? The researchers will compare taVNS with a control group (sham stimulation/placebo) to determine whether the intervention leads to better clinical and functional outcomes in patients undergoing coronary artery bypass grafting.

Participants will:

  • Receive sessions of transcutaneous auricular vagus nerve stimulation (taVNS) or sham stimulation (placebo), according to the study randomization.
  • Undergo assessments of autonomic modulation using heart rate variability before and after the intervention.
  • Be evaluated for inflammatory markers, pain intensity, quality of life, and functional capacity at different time points during the postoperative period.

Full description

Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide. Coronary artery bypass grafting (CABG) is frequently indicated in patients with advanced disease. However, the postoperative period is associated with autonomic dysfunction, characterized by increased sympathetic activity and reduced vagal tone, which may contribute to cardiovascular complications and prolonged recovery.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive technique that involves electrical stimulation of the auricular branch of the vagus nerve. By modulating autonomic activity, taVNS may represent a complementary approach to supporting postoperative recovery. However, evidence regarding its application in the immediate postoperative period following CABG remains limited.

This randomized controlled clinical trial aims to investigate the effects of taVNS on autonomic modulation in patients undergoing CABG, as well as to assess the safety and tolerability of the intervention.

The study will be coordinated by Hospital de Clínicas de Porto Alegre (HCPA), the sponsoring institution, while participant recruitment and data collection will be conducted at Hospital de Clínicas de Ijuí (HCI), the collaborating center.

Eligible participants will be randomly assigned to either an active stimulation group or a sham control group. Randomization will be performed using a random number sequence.

Participants assigned to the intervention group will receive transcutaneous auricular vagus nerve stimulation using the EL-30 device (NKL). The electrodes will be positioned on the left cymba conchae and the left earlobe. Stimulation will be delivered in daily 30-minute sessions throughout the hospital stay, using a pulse width of 250 μs, an intensity below the pain threshold, and alternating frequencies of 2 Hz and 15 Hz at 5-second intervals.

Participants in the control group will undergo the same procedure using the same device and electrode placement, but without active electrical stimulation. Each session will also last 30 minutes.

The intervention will begin during the postoperative period and will be administered under clinical supervision by trained healthcare professionals. Assessments will be conducted according to the study protocol, including measurements before and after stimulation sessions and at hospital discharge.

Heart rate variability (HRV) will be assessed using electrocardiography and a Polar H10 heart rate sensor. Recordings will be obtained with participants in the supine position after a 5-minute resting period, followed by 5-minute recordings.

The study will also include clinical and functional assessments during the postoperative period and at hospital discharge, according to the study protocol.

Potential risks associated with the intervention include mild discomfort, tingling, or itching at the stimulation site. Bradycardia may occur in susceptible individuals, who will be monitored during the procedure. Participants will be monitored throughout the intervention, and stimulation will be discontinued if clinically necessary.

The study will be conducted in accordance with applicable ethical standards and Brazilian regulations for research involving human participants. Written informed consent will be obtained before participation. Participant confidentiality and data privacy will be maintained throughout the study.

Enrollment

58 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients aged ≥18 years who are undergoing coronary artery bypass grafting (CABG), are able to understand and comply with the study protocol, and provide written informed consent

Exclusion Criteria:

  • History of severe cardiac arrhythmias or recent electrical instability, including permanent atrial fibrillation, tachyarrhythmias, or the presence of an implantable cardioverter-defibrillator (ICD).
  • Presence of a pacemaker or other implanted electronic devices.
  • Severe neurological or psychiatric disorders, such as epilepsy, schizophrenia, or recent stroke (within the past 6 months).
  • Active chronic inflammatory or autoimmune diseases that may interfere with inflammatory markers (e.g., systemic lupus erythematosus or rheumatoid arthritis).
  • Acute infection or fever at the time of screening.
  • History of ear surgery or ear injury that would preclude the application of transcutaneous auricular vagus nerve stimulation (taVNS).
  • Confirmed or suspected pregnancy (for female participants of childbearing potential).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

58 participants in 2 patient groups, including a placebo group

Intervention Group
Active Comparator group
Description:
Transcutaneous auricular stimulation of the auricular branch of the vagus nerve with daily 30-minute sessions until hospital discharge. A transcutaneous electrode will be positioned on the concha, and the other electrode on the left earlobe. In this manner, we will stimulate the vagus nerve at the concha and the great auricular nerve at the earlobe. These sites were selected based on the innervation of the ear, technical feasibility for electrode placement, and to standardize the treatment protocol. In our study, the device used will be the EL-30 (NKL Produtos Eletrônicos, Brusque, SC, Brazil), with the following stimulation parameters: pulse width of 250 μs, intensity below the pain threshold, 5 seconds at 2 Hz / 5 seconds at 15 Hz. Recent studies have demonstrated that low frequencies have a greater effect on reducing sympathetic activity, whereas frequencies in the range of 10-25 Hz produce effective parasympathetic modulation. We selected a mixed mode, using both low (2 Hz) and me
Treatment:
Device: Transcutaneous auricular vagus nerve stimulation
Control Group
Placebo Comparator group
Description:
The same device and electrodes used in the intervention group will be applied. No actual electrical current will be delivered. The session duration will be 30 minutes, with the same electrode placement and application positioning as the intervention group.
Treatment:
Device: Transcutaneous auricular vagus nerve stimulation

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems